Cargando…
Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer According to Somatic Damage DNA Repair Gene Alterations
(1) Background: In literature, approximately 20% of mCRPC present somatic DNA damage repair (DDR) gene mutations, and their relationship with response to standard therapies in mCRPC is not well understood. The objective was to evaluate outcomes of mCRPC patients treated with standard therapies accor...
Autores principales: | Neviere, Zoé, Coquan, Elodie, Brachet, Pierre-Emmanuel, Meriaux, Emeline, Bonnet, Isabelle, Krieger, Sophie, Castéra, Laurent, Vaur, Dominique, Boulouard, Flavie, Leconte, Alexandra, Lequesne, Justine, Lelaidier, Anais, Ricou, Agathe, Joly, Florence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030073/ https://www.ncbi.nlm.nih.gov/pubmed/35448200 http://dx.doi.org/10.3390/curroncol29040226 |
Ejemplares similares
-
CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure
por: Coquan, Elodie, et al.
Publicado: (2021) -
TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma
por: Coquan, Elodie, et al.
Publicado: (2022) -
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
por: Lesueur, Paul, et al.
Publicado: (2019) -
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR)
por: Dos Santos, Mélanie, et al.
Publicado: (2022) -
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
por: Leman, Raphaël, et al.
Publicado: (2023)